333 Bay St, Suite 2400, Bay Adelaide Ctr, Box 20, Toronto, ON
Year called to bar: 2000 (ON)
John Sabetti practises primarily in the areas of securities, mergers, acquisitions and corporate commercial law. With significant experience in corporate finance and M&A transactions, John regularly assists clients with structuring and leading initial public offerings, private placements, acquisition financing, takeover bids, business combinations, debt offerings and redomiciling transactions. In his corporate commercial practice, John has acted for public companies and some of Canada’s largest private corporations and their shareholders. With experience in a broad range of corporate matters, John regularly advises clients with structuring joint venture and shareholder arrangements, as well as the purchase and sale of businesses and corporate reorganizations, in a wide range of industries, including manufacturing, high tech, and construction equipment rental. From a capital markets perspective, John has participated in numerous public and private capital raising transactions in a broad range of sectors including mining, healthcare and technology.
On October 1, 2018, Just Energy Group Inc. (“Just Energy” or the “Company”), a leading consumer company specializing in electricity and natural gas commodities, energy efficiency solutions, and renewable energy options, completed its acquisition of all of the issued and the outstanding shares of Filter Group Inc. (“Filter Group”) through a wholly-owned subsidiary of the Company for $15 million in cash consideration, the assumption of approximately $22 million of Filter Group debt, and future performance based earn-out payments of up to approximately $42 million.
On August 3, 2016, Golden Star Resources Ltd. (“Golden Star”) completed a public offering in Canada and the United States of 46 million common shares (the “Common Shares”) at a price of US$0.75 per Common Share, for aggregate gross proceeds of US$34.5 million (the “Equity Offering”), which included the full exercise of an over-allotment option granted to the underwriters.
On October 21, 2015, Concordia Healthcare Corp. (“Concordia”), a diverse healthcare company focused on legacy pharmaceutical products and orphan drugs, acquired UK-based Amdipharm Mercury Limited (“AMCo”) from Cinven Ltd, a leading European private equity firm, for approximately US$3.3 billion (the “Acquisition”) paid through a combination of cash and the issuance of 8.49 million common shares of Concordia.
On April 21, 2015, Concordia Healthcare Corp. (Concordia), a diverse healthcare company focused on legacy pharmaceutical products and orphan drugs, acquired 18 products from Covis Pharma S.à.r.l and Covis Injectables, S.à.r.l (collectively, Covis). The purchase price of US$1.2 billion was paid in cash at closing.